Medication development for agitation and aggression in Alzheimer disease: Review and discussion of recent randomized clinical trial design

International Psychogeriatrics

Volumn 27, Issue 2, 2015, Pages 181-197

  Soto, Maria ^a   Andrieu, Sandrine ^a   Nourhashemi, Fati ^a   Ousset, Pierre Jean ^a   Ballard, Clive ^b   Robert, Philippe ^c   Vellas, Bruno ^a   Lyketsos, Constantine G ^d   Rosenberg, Paul B ^d  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c University of Côte d Azur   (France)

^d JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

aggression; agitation; Alzheimer's; behavior; clinical trial; measurement; therapeutics

Indexed keywords

ARIPIPRAZOLE; BREXPIPRAZOLE; CITALOPRAM; DEXTROMETHORPHAN PLUS QUINIDINE; DRONABINOL; ESCITALOPRAM; INOSITOL DERIVATIVE; MELATONIN; MEMANTINE; MIBAMPATOR; OXCARBAZEPINE; PLACEBO; PRAZOSIN; RISPERIDONE; SCYLLO INOSITOL; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; CAREGIVER; DEMENTIA; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STUDY DESIGN;

EID: 84927516526     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610214001720     Document Type: Review

References (84)

1. Ballard, C., Francis, P. and Corbett, A. (2013). Randomized controlled trial of mibampator for behavioral and psychological symptoms of dementia: comments on the trial and thoughts for future studies. International Psychogeriatrics, 25, 687-689.
2. Ballard, C. and Howard, R. (2006). Neuroleptic drugs in dementia: benefits and harm. Nature Reviews Neuroscience, 7, 492-500.
3. Ballard, C. et al. (2009). Management of agitation and aggression associated with Alzheimer's disease. Nature Reviews Neurology, 2, 245-255.
4. Benoit, M. et al. (2006). Professional consensus on the treatment of agitation, aggressive behaviour, oppositional behaviour and psychotic disturbances in dementia. Journal of Nutrition Health and Aging, 10, 410-415.
5. Blanchard, B. J., Chen, A., Rozeboom, L. M., Stafford, K. A., Weigele, P. and Ingram, V. M. (2004). Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. Proceedings of the National Academy of Sciences USA, 101, 14326-14332.
6. Brodaty, H. and Arasaratnam, C. (2012). Meta-Analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. American Journal of Psychiatry, 169, 946-953.
7. Canevelli, M. et al. (2013). Behavioral and psychological subsyndromes in Alzheimer's disease using the neuropsychiatric inventory. International Journal of Geriatric Psychiatry, 28, 795-803.
8. Cohen-Mansfield, J. (1996). Conceptualization of agitation: results based on the Cohen-Mansfield agitation inventory and the agitation behavior mapping instrument. International Psychogeriatrics, 8, 309-315.
9. Cohen-Mansfield, J., Werner, P., Watson, V. and Pasis, S. (1995). Agitation among elderly persons at adult day-care centers: the experiences of relatives and staff members. International Psychogeriatrics, 7, 447-458.
10. Cummings, J. L. (1997). The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology, 48, S10-S16.
11. Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A. and Gornbein, J. (1994). The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology, 44, 2308-2314.
12. Cummings, J. L. et al. (2013). Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet, 383, 533-540.
13. de Deyn, P. P. et al. (1999). A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology, 53, 946-955.
14. de Medeiros, K. et al. (2010). The neuropsychiatric inventory-clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. International Psychogeriatrics, 22, 984-994.
15. Dennehy, E. B., Kahle-Wrobleski, K., Sarsour, K. and Milton, D. R. (2012). Derivation of a brief measure of agitation and aggression in Alzheimer's disease. International Journal of Geriatric Psychiatry, 28, 182-189.
16. Deudon, A. et al. (2009). Non-pharmacological management of behavioural symptoms in nursing homes. International Journal of Geriatric Psychiatry, 24, 1386-1395.
17. Donohue, M. C. and Ainsen, P. S. (2012). Mixed model of repeated measures versus slope models in Alzheimer's disease clinical trials. Journal of Nutrition Health and Aging, 16, 360-364.
18. Drye, L. T. et al. (2012). CitAD Research Group. Citalopram for agitation in Alzheimer's disease: design and methods. Alzheimer's and Dementia, 8, 121-130.
19. Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975). "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatry Research, 12, 196-198.
20. Fox, C. et al. (2012). Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS One, 7, e35185.
21. Frost, C., Michael, G., Kenward, I. and Fox, C. (2008). Optimizing the design of clinical trials where the outcome is a rate. Can estimating a baseline rate in a run-in period increase efficiency? Statistical Medicine, 27, 3717-3731.
22. Galasko, D. et al. (1997). An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's disease cooperative study. Alzheimer Disease and Associated Disorders, 11, S33-S39.
23. Garre-Olmo, J., López-Pousa, S., Vilalta-Franch, J., de Gracia Blanco, M. and Vilarrasa, A. B. (2010). Grouping and trajectories of neuropsychiatric symptoms in patients with Alzheimer's disease. Part II: two-year patient trajectories. Journal of Alzheimers Disease, 22, 1169-1180.
24. Gauthier, S. et al. (2010). Management of behavioral problems in Alzheimer's disease. International Psychogeriatrics, 22, 346-372.
25. Geda, Y. E. et al. (2013). Neuropsychiatric syndromes professional interest area of ISTAART. Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimer's and Dementia, 9, 602-608.
26. Gehrman, P. R., Connor, D. J., Martin, J. L., Shochat, T., Corey-Bloom, J. and Ancoli-Israel, S. (2009). Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. American Journal of Geriatric Psychiatry, 17, 166-169.
27. Gitlin, L. N., Kales, C. K. and Lyketsos, C. G. (2012). Nonpharmacologic management of behavioral symptoms in dementia. Journal of the American Medical Association, 308, 2020-2029.
28. Gonfrier, S., Andrieu, S., Renaud, D., Vellas, B. and Robert, P. H. (2012). Course of neuropsychiatric symptoms during a 4-year follow up in the REAL-FR cohort. Journal of Nutrition Health and Aging, 16, 134-137.
29. Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda, MD: US Department of Health, Education, and Welfare.
30. Herrmann, N., Gauthier, S., Boneva, N. and Lemming, O. M. (2013). A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease. International Psychogeriatrics, 25, 919-927.
31. Howard, R. J. et al. (2007). Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine, 357, 1382-1392.
32. Husebo, B. S., Ballard, C., Sandvik, R., Nilsen, O. B. and Aarsland, D. (2011). Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ, 343, d4065.
33. Iovieno, N. and Papakostas, G. I. (2012). Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder Journal of Clinical Psychiatry, 73, 676-683.
34. Kairalla, J. A., Coffey, C. S., Thomann, M. A. and Muller, K. E. (2012). Adaptive trial designs: a review of barriers and opportunities. Trials, 13, 145.
35. Kales, H. C.,Gitlin, L. N. and Lyketsos, C. (2014) (For the Detroit Expert Panel on the Assessment and Management of Neuropsychiatric Symptoms of Dementia). Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. Journal of the American Geriatrics Society, 62, 762-769.
36. Kales, H. C. et al. (2012). Risk of mortality among individual antipsychotics in patients with dementia. American Journal of Psychiatry, 169, 71-79.
37. Kirste, T. et al. (2014). Detecting the effect of Alzheimer's disease on everyday motion behavior. Journal of Alzheimers Disease, 38, 121-132.
38. Lai, M. K. et al. (2003). Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Research, 974, 82-87.
39. Langballe, E. M., Engdahl, B., Nordeng, H., Ballard, C., Aarsland, D. and Selbaek, G. (2013). Short-And long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. American Journal of Geriatric Psychiatry, 22, 321-331.
40. Logsdon, R. G., Gibbons, L. E., McCurry, S. M. and Teri, L. (2002). Assessing quality of life in older adults with cognitive impairment. Psychosomatic Medicine, 64, 510-519.
41. Lonergan, E., Luxenberg, J., Colford, J. M. and Birks, J. (2002). Haloperidol for agitation in dementia. Cochrane Database of Systematic Reviews, Issue 2, CD002852.
42. Lyketsos, C. G., Steinberg, M., Tschanz, J. T., Norton, M. C., Steffens, D. C. and Breitner, J. C. (2000). Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. American Journal of Geriatric Psychiatry, 157, 708-714.
43. Lyketsos, C. G. et al. (2006). Task Force of American Association for Geriatric Psychiatry. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. American Journal of Geriatric Psychiatry, 14, 561-572.
44. Lyketsos, C. G. et al. (2011). Neuropsychiatric symptoms in Alzheimer's disease. Alzheimer's and Dementia, 7, 532-539.
45. Maher, A. R. et al. (2011). Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-Analysis. JAMA, 28, 306, 1359-1369.
46. Mahlberg, R., Walther, S., Eichmann, U., Tracik, F. and Kunz, D. (2007). Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study. Archives of Gerontolology Geriatric, 45, 19-26.
47. McKhann, G. et al. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology, 34, 939-944.
48. McKhann, G. M. et al. (2011). The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 7, 263-269.
49. Molnar, F., Man-Son-Hing, M. and Dean Fergusson, D. (2009). Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. Journal of the American Geriatrics Society, 57, 536-546.
50. Mowla, A. and Pani, A. (2010). Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease. A double-blind, randomized clinical trial. Journal of Clinical Psychopharmacology, 30, 40-43.
51. Mugno, R., Zhus, W. and Rosenberger, W. F. (2004). Adaptive urn designs for estimating several percentiles of a dose-response curve. Statistical Medicine, 23, 2137-2150.
52. Murman, D. L., Chen, Q., Powell, M. C., Kuo, S. B., Bradley, C. J. and Colenda, C. C. (2002). The incremental direct costs associated with behavioral symptoms in AD. Neurology, 59, 1721-1729.
53. Okura, T. and Langa, K. M. (2011). Caregiver burden and neuropsychiatric symptoms in older adults with cognitive impairment: the Aging, Demographics, and Memory Study (ADAMS). Alzheimer Disease and Associated Disorders, 25, 116-121.
54. Okura, T., Plassman, B. L., Steffens, D. C., Llewellyn, D. J., Potter, G. G. and Langa, K. M. (2010). Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the aging, demographics, and memory study. Journal of the American Geriatrics Society, 58, 330-337.
55. Okura, T., Plassman, B. L., Steffens, D. C., Llewellyn, D. J., Potter, G. G. and Langa, K. M. (2011). Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. Journal of the American Geriatrics Society, 59, 473-481.
56. O'Neill, M. J. (2004). SMi 4th Annual Conference on Neurodegenerative Disorders: a focus on Alzheimer's and Parkinson's disease. Expert Opinion on Investigational Drugs, 13, 1369-1373.
57. Porsteinsson, A. P. et al. (2014). Effect of citalopram on agitation in Alzheimer's disease-the CitAD randomized controlled trial. Journal of the American Medical Association, 311, 682-691.
58. Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W. and Cleusa, P. (2013). The global prevalence of dementia: a systematic review and meta-Analysis. Alzheimer's and Dementia, 9, 63-75.
59. Rabins, P. V. et al. (2007). APA work group on Alzheimer's disease and other dementias; steering committee on practice guidelines. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias: second edition. American Journal of Psychiatry, 164(S), 5-56.
60. Ramírez, B. G. et al. (2005). Prevention of Alzheimer's disease pathology by cannabinoids: neuro-protection mediated by blockade of microglial activation. Journal of Neurosciences, 25, 1904-1913.
61. Rappaport, S. A., Marcus, R. N., Manos, G., McQuade, R. D. and Oren, D. A. (2009). A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia. Journal of the American Medical Directors Association, 10, 21-27.
62. Richter, T. et al. (2012). Psychosocial interventions for reducing antipsychotic medication in care home residents. The Cochrane Database of Systemetic Reviews, 12, CD008634.
63. Rosen, W. G., Mohs, R. C. and Davis, K. L. (1984). A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 141: 1356-1364.
64. Rosenberg, P. B. et al. (2010). Sertraline for the treatment of depression in Alzheimer disease: DIADS-2 Research Group. American Journal of Geriatric Psychiatry, 18, 136-145.
65. Salzman, C. et al. (2008). Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. Journal of Clinical Psychiatry, 69, 889-898.
66. Schneider, L. S., Dagerman, K. and Insel, P. (2006). Efficacy and adverse effects of atypical antipsychotics for dementia: meta-Analysis of randomized, placebo-controlled trials. American Journal of Geriatric Psychiatry, 14, 191-210.
67. Schneider, L. S., Pollock, V. E. and Lyness, S. A. (1990). A meta-Analysis of controlled trials of neuroleptic treatment in dementia. Journal of the American Geriatrics Society, 38, 553-563.
68. Schneider, L. S. et al. (1997). Validity and reliability of the Alzheimer's Disease Cooperative Study-clinical global impression of change. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders, 11, S22-S32.
69. Selbaek, G., Høgset, L. D., Söderhamn, U. and Kirkevold, O. (2013). The course of neuropsychiatric symptoms in nursing-home patients with dementia over a 53-month follow-up period. International Psychogeriatrics, 20, 1-9.
70. Siddiqui, O., hung, M. J. and O'neill, R. (2009). MMRM versus LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. Journal of Biopharmaceutical Statistics, 19, 227-246.
71. Sommer, O. H., Aga, O., Cvancarova, M., Olsen, I. C., Selbaek, G. and Engedal, K. (2009). Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia. Dementia and Geriatric Cognitive Disorders, 27, 155-163.
72. Soto, M. E. et al. (2012). Improving care of older adults with dementia: description of 6299 hospitalizations over 11 years in a special acute care unit. Journal of the American Medical Directors Association, 13, 486,.e1-6.
73. Steinberg, M. and Lyketsos, C. G. (2008). Neuropsychiatric measures for cognitive disorders. In A. J. Rush, M. B. First and D. Blacker (eds.), Handbook of Psychiatric Measures (p. 864). Arlington, VA: American Psychiatric Publishing.
74. Steinberg, M. et al. (Cache County Investigators). (2008). Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. International Journal of Geriatric Psychiatry, 23, 170-177.
75. Szot, P., White, S. S., Greenup, J. L., Leverenz, J. B., Peskind, E. R. and Raskind, M. A. (2007). Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes. Neuroscience, 146, 471-480.
76. Tariot, P. et al. (2011). Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of General Psychiatry, 68, 853-886.
77. Teri, L. et al. (2000). Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 55, 1271-1278.
78. Townsend, M. et al. (2006). Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Annals of Neurolology, 60, 668-676.
79. Trzepacz, P. T. et al. (2013a). Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. International Psychogeriatrics, 25, 707-719.
80. Trzepacz, P. T. et al. (2013b) Alzheimer's disease neuroimaging initiative. Subscale validation of the neuropsychiatric inventory questionnaire: comparison of Alzheimer's disease neuroimaging initiative and national Alzheimer's coordinating center cohorts. American Journal of Geriatric Psychiatry, 21, 607-622.
81. Wang, L. Y. et al. (2009). Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. American Journal of Geriatric Psychiatry, 17, 744-751.
82. Woodward, M. R., Harper, D. G., Stolyar, A., Forester, B. P. and Ellison, J. M. (2014). Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. American Journal of Geriatric Psychiatry, 22, 415-419.
83. Yamada, K. A. (2000). Therapeutic potential of positive AMPA receptor modulators in the treatment of neurological disease. Expert Opinion on Investigational Drugs, 9, 765-778.
84. Zarit, S. H., Reever, K. E. and Bach-Peterson, J. (1980). Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist, 20, 649-655.